The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit

Not Applicable

• Conditions: Acute Coronary Syndrome
• Interventions: Behavioral: pharmaceutical care service

• Registration Number: NCT02922140
• Lead Sponsor: Ain Shams University

Brief Summary

This study aims to investigate the role of clinical pharmacist in the development of a pharmaceutical care program for patients with Acute coronary syndrome tailored to their specific learning needs and their cultural context, and to verify the program's effects on physiological factors and recurrent symptoms or cardiac events.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-09
• Study First Submitted: 2016-09-20
• Study First Submitted QC: 2016-09-30
• Study First Posted: 2016-10-04
• Status Verified: 2016-12
• Last Update Submitted: 2016-12-12
• Last Update Posted: 2016-12-13
• Primary Completion: 2017-08
• Study Completion: 2017-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Are diagnosed with Acute coronary syndrome (ischemic heart disease) by their primary cardiologist, treated with medication, percutaneous coronary angioplasty, or coronary artery bypass graft.
2. At 20-79 years of age.
3. Has the ability to perform regular physical activity according to the patients' self-identification and the judgment of their primary cardiologist.
4. Willing to participate in this study.
5. Able to be reached by telephone postdischarge.

Exclusion Criteria

1. Patients with cognitive impairment.
2. If they need professional help to take their medication at home.
3. With terminal illness.
4. Inability to communicate.
5. Severe arrhythmia.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
intervention group	pharmaceutical care service	will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.

Primary Outcome Measures

Name	Time	Method
Change in the level of patient education about disease, drugs and lifestyle modification using coronary artery disease education questionnaire (CADE-Q)	three months	at baseline and after three months
Change in the number of solved drug-related problems	three months	assessment of drug-related problems at baseline and solving them during three months
Assessment of medications adherence: (Eight-item Morisky adherence questionnaire).	three months	at baseline and after three months

Secondary Outcome Measures

Name	Time	Method
Assessment of quality of life: (36-items self-care Health survey (SF-36)).	three months	at baseline and after three months
Assessment of smoker's dependence on cigarette smoking: (using the Fagerstrom Test for Nicotine Dependence).	three months	at baseline and after three months
Change in heart rate [HR] (Bpm).	three months	at baseline and after three months
Change in Lipid profile : total cholesterol (mg/dl), triglycerides(mg/dl), and low density lipoprotein cholesterol(mg/dl), high density lipoprotein (mg/dl)	three months	at baseline and after three months
Change in levels of fasting blood glucose (mg/dl)	three months	at baseline and after three months
Change in systolic and diastolic blood pressure [BP] (mmHg).	three months	at baseline and after three months

Trial Locations

Locations (1)

Ain Shams University; 🇪🇬 Cairo, Egypt